Pediatric systemic lupus erythematosus (SLE) is associated with high disease severity and significantly higher morbidity and mortality compared to adult-onset SLE, making it a particularly challenging condition to manage. Chimeric antigen receptor (CAR) T-cell therapy holds significant promise for improving outcomes in refractory pediatric SLE. However, the use of CAR T-cell therapy in pediatric patients presents unique challenges, including difficulty in collecting sufficient T cells. Pediatric patients may experience distinct side effects, such as age-specific toxicities or more pronounced neurotoxic events, requiring tailored monitoring and management. Additionally, the psychological impact on children and their families, facing potentially life-threatening treatment protocols, must be carefully addressed. To date, only four children with SLE have been treated with CAR T cells, highlighting the early stage of research in this area. The clinical outcomes provide hope that CAR T-cell therapy could offer a breakthrough in treating pediatric SLE; however, main limitations remain the small number of patients and the relatively short follow-up. More data are needed to fully assess the safety, efficacy, and long-term outcomes in this vulnerable population.<Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec align="left" colname="c1" colnum="1" /> <colspec align="left" colname="c2" colnum="2" /> <tbody> <row> <entry nameend="c2" namest="c1"> Key Points • Pediatric SLE is characterized by more severe manifestations, higher morbidity, and increased mortality compared to adult-onset SLE. • CAR T-cell therapy shows promise as a potential treatment for refractory pediatric SLE aiming ideally towards long-term, drug-free remission. • CAR T-cell therapy in pediatric SLE presents unique challenges, including age-related toxicities, technical difficulties, and ethical considerations. • To date, results are available from only a handful of children with SLE treated with CAR T cells. Expected advancements in CAR T-cell technology, along with data from ongoing clinical trials involving children with SLE, will determine the pace and extent of CAR T-cell therapy application in pediatric SLE. </entry> </row> </tbody> </tgroup> </Table>

CAR T cells in pediatric systemic lupus erythematosus

期刊论文
出版模式：

开放获取
发表日期：

2025年7月11日

查看全文

Theodora Simopoulou,
Athanasios Gkoutzourelas,
Christina G. Katsiari

摘要

Pediatric systemic lupus erythematosus (SLE) is associated with high disease severity and significantly higher morbidity and mortality compared to adult-onset SLE, making it a particularly challenging condition to manage. Chimeric antigen receptor (CAR) T-cell therapy holds significant promise for improving outcomes in refractory pediatric SLE. However, the use of CAR T-cell therapy in pediatric patients presents unique challenges, including difficulty in collecting sufficient T cells. Pediatric patients may experience distinct side effects, such as age-specific toxicities or more pronounced neurotoxic events, requiring tailored monitoring and management. Additionally, the psychological impact on children and their families, facing potentially life-threatening treatment protocols, must be carefully addressed. To date, only four children with SLE have been treated with CAR T cells, highlighting the early stage of research in this area. The clinical outcomes provide hope that CAR T-cell therapy could offer a breakthrough in treating pediatric SLE; however, main limitations remain the small number of patients and the relatively short follow-up. More data are needed to fully assess the safety, efficacy, and long-term outcomes in this vulnerable population.

Key Points

• Pediatric SLE is characterized by more severe manifestations, higher morbidity, and increased mortality compared to adult-onset SLE.

• CAR T-cell therapy shows promise as a potential treatment for refractory pediatric SLE aiming ideally towards long-term, drug-free remission.

• CAR T-cell therapy in pediatric SLE presents unique challenges, including age-related toxicities, technical difficulties, and ethical considerations.

• To date, results are available from only a handful of children with SLE treated with CAR T cells. Expected advancements in CAR T-cell technology, along with data from ongoing clinical trials involving children with SLE, will determine the pace and extent of CAR T-cell therapy application in pediatric SLE.